Inquiry Basket
Loading ......
Filter By Product Search for
METH
METH Full Name
Methamphetamine
METH Introduction
Methamphetamine is a potent psychostimulant whose biological effects extend far beyond a single receptor or signaling pathway, making it a highly relevant research target in neuroscience, pharmacology, toxicology, and addiction biology. Researchers seeking to understand methamphetamine use disorder (MUD) increasingly focus on the molecular networks that regulate dopamine homeostasis, neuronal plasticity, and long-term brain remodeling. Among the most important molecular targets are the dopamine transporter (DAT/SLC6A3), vesicular monoamine transporter 2 (VMAT2/SLC18A2), dopamine receptors (particularly DRD1, DRD2, and DRD3), serotonin transporter (SERT/SLC6A4), norepinephrine transporter (NET/SLC6A2), and intracellular signaling pathways associated with oxidative stress and neuroinflammation. Methamphetamine enters presynaptic neurons primarily through DAT, disrupts vesicular dopamine storage by interacting with VMAT2, and promotes reverse dopamine transport, resulting in excessive extracellular dopamine accumulation. This abnormal neurotransmitter surge underlies both the intense rewarding effects of the drug and the progressive neuronal injury observed after repeated exposure. Recent bibliometric analyses further demonstrate that addiction, dopamine signaling, neurotoxicity, gene expression, genetic polymorphisms, DNA methylation, and epigenetic regulation have become the dominant research themes, reflecting a shift toward understanding methamphetamine-induced molecular adaptations rather than only its acute pharmacological effects.
From a functional perspective, methamphetamine profoundly alters multiple biological processes that control synaptic transmission, neuronal survival, and cognitive function. Acute exposure produces excessive activation of dopaminergic circuits involved in reward, motivation, learning, and reinforcement, while chronic exposure induces widespread transcriptional and epigenetic remodeling across brain regions including the striatum, nucleus accumbens, hippocampus, and prefrontal cortex. Experimental studies demonstrate that methamphetamine reduces functional DAT expression at the cell surface, alters VMAT2 activity, and modifies dopamine receptor signaling, particularly increasing DRD3 expression during behavioral sensitization. In parallel, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, and calcium dysregulation activate apoptotic pathways characterized by increased expression of Bax, Bad, Bid, and p53 together with reduced Bcl-2 and Bcl-XL activity, ultimately promoting neuronal degeneration. Methamphetamine also stimulates microglial activation and neuroinflammatory responses through elevated expression of TNF-α, IL-1β, IL-6, and other inflammatory mediators, creating a persistent inflammatory environment that contributes to long-term cognitive impairment. These interconnected molecular mechanisms explain why methamphetamine remains an important experimental model for investigating neurotransmitter regulation, synaptic plasticity, neurodegeneration, and brain resilience following repeated stimulant exposure.
Methamphetamine-associated molecular targets are closely linked to numerous neurological and psychiatric disorders, making them valuable biomarkers and potential therapeutic targets. Variants in genes encoding DAT (SLC6A3), VMAT2 (SLC18A2), dopamine receptors (DRD1, DRD2, DRD3), catechol-O-methyltransferase (COMT), monoamine oxidases (MAOA and MAOB), and brain-derived neurotrophic factor (BDNF) have been associated with susceptibility to methamphetamine use disorder, treatment response, cognitive decline, and relapse risk. Systematic reviews and meta-analyses support a central role for dopaminergic genetic variation in determining individual vulnerability, while emerging evidence suggests that epigenetic mechanisms, including DNA methylation and chromatin remodeling, may partly explain persistent behavioral changes long after drug cessation. Beyond addiction, methamphetamine-induced alterations have been implicated in neurodegenerative disorders, mood disorders, psychosis, cardiovascular injury, and developmental abnormalities following prenatal exposure. Current translational research therefore aims not only to identify genetic risk factors but also to develop precision medicine strategies that integrate molecular biomarkers, pharmacogenomics, neuroimaging, and cognitive assessment. As understanding of DAT-, VMAT2-, and inflammation-related pathways continues to improve, these targets are expected to support the discovery of more effective interventions for methamphetamine dependence while also advancing broader research into dopamine-related neurological diseases and neuroprotective therapies.
Alternate Names for METH
Methamphetamine;
Loading ......
